Embryonic mortality after embryo transfer causes substantial economic losses in the cattle industry. This has been related to the inability of the corpus luteum (CL) to secrete enough progesterone (P4) to prepare the endometrium for embryo implantation and maintain pregnancy. Thus, the objective of this experiment was to evaluate the effects of treatments that induce ovulation of a persistent follicle and formation of a larger CL that secretes more P4 on the conception rate (number pregnant/number that received an embryo) of recipients following embryo transfer. Two hundred seventy-eight crossbred Bos taurus x Bos indicus heifers were randomly allocated to one of four groups. Group 1 (G1, n = 70) received 2 mg estradiol benzoate (EB) + 50 mg of P4 at the time a progesterone-releasing intravaginal device (CIDR®) was inserted (Day 0), 0.53 mg of cloprostenol (PGF2α; prostaglandin F2α analogue) at the time of CIDR® removal (Day 8), and 0.5 mg EB on Day 9. Group 2 (G2, n = 71) received a CIDR® and 2 mg of EB + 50 mg of P4 at CIDR insertion (Day 0) and a PGF2α treatment on Day 0 and Day 5. The CIDR® was removed on Day 14, and 0.5 mg of EB was given on Day 15. Group 3 (G3, n = 67) was similar to G2, except that an injection of PGF2α was given on Day 5. Group 4 (n = 70) was similar to G2, however, these heifers received PGF2α both at the time of CIDR® insertion and removal. Eight days after the second EB administration, heifers of all groups were selected to receive a frozenthawed in vivo produced embryo by direct transfer. Mean (± SEM) diameter (mm) of the dominant follicle one day after CIDR® removal was larger in heifers in G2 (11.1 ± 0.3), G3 (10.6 ± 0.4), and G4 (10.6 ± 0.3) than in G1 (7.8 ± 0.4). The mean CL area (cm2 ), plasma P4 concentrations (ng/ml), and recipient selection rate (number that received an embryo/number in treatment group) was greater in G2 (2.3 ± 0.1; 3.8 ± 0.2; 77.4%) and G3 (2.4 ± 0.1; 3.8 ± 0.3; 74.6%) than in G1 (1.9 ± 0.1; 2.3 ± 0.2; 51.4%), but mean values in G4 (2.2 ± 0.1; 3.1 ± 0.3; 68.6%) were not different from those of other groups. Conception rate was lower in G2 (38.9%; 21/55) and G3 (37.1%; 19/50) than in G1 (59.1%; 21/36), but conception rate in G4 (50.0%; 21/36) was not different from that of the other groups. Pregnancy rate (number pregnant/number in treatment group) was not different among groups. These results showed that a long-term CIDR® treatment with PGF2α administered at the beginning of the treatment effectively caused the formation and ovulation of a persistent follicle and resulted in a larger CL that provided a higher P4 concentration. However, the induction of a persistent follicle reduced conception rates following embryo transfer.